TTTiago Teixeira

Tiago Teixeira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tiago Teixeira has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epidemiology and predictors of 30-day mortality in clinically significant Clostridium species infections

    by Ana Gorgulho, Ana Rita Paixão, Ana Sofia Reis, Dara Mbanze, Gabriela Abreu, Celina Gonçalves, Cristóvão Figueiredo, Tiago Teixeira, Luís Malheiro

    Purpose: Clostridium species are an under-recognized cause of severe infections with substantial mortality, yet national data remain limited. This study aimed to characterize the epidemiological, microbiological, clinical, and therapeutic features of clinically significant Clostridium spp. infections and to identify factors associated with 30-day mortality. Methods: We conducted a retrospective, single-centre cohort study at Unidade Local de Saúde de Gaia-Espinho (Portugal), including all patients with clinically significant Clostridium spp. isolates between 1 January 2020 and 30 March 2025. Demographic, clinical, microbiological, and therapeutic data were obtained from electronic medical and laboratory records. The primary outcome was 30-day all-cause mortality. Survivors and non-survivors were compared using univariate and multivariable logistic regression analyses. Results: A total of 119 patients were included (median age 68.9 years). Most infections were community-acquired (73.1%), and C. perfringens was the most frequently identified species (58.8%). Thirty-day mortality was 22.7%. In univariate analysis, mortality was associated with older age, thrombocytopenia, hepatic and renal dysfunction, bacteremia, sepsis or septic shock, inadequate antimicrobial therapy, and lack of source control. In Firth penalised logistic regression, age (OR 1.09/year, 95% CI 1.04–1.16), hepatic dysfunction (OR 6.74, 95% CI 2.05–25.87), and septic shock (OR 56.41, 95% CI 11.11–458.37) were associated with mortality; adequate antimicrobial therapy was protective (OR 0.09, 95% CI 0.02–0.37). Conclusion: Clostridium spp. infections were associated with high mortality. Age and organ dysfunction were key risk factors, whereas early appropriate antimicrobial therapy was the main modifiable protective factor. Prompt recognition, timely antibiotics, and adequate source control are essential.

  • Open Access

    HIV-Related Stigma in People Living with HIV: A Cross-Sectional Analysis of a Portuguese Clinical Cohort

    by Helder Gemo, Ana Gorgulho, Francisca Bartilotti, Dara Mbanze, Cristóvão Figueiredo, Joana Fragoso, Sofia Nunes, Daniel Coutinho, Carlos Azevedo, Tiago Teixeira, et al.

    HIV-related stigma remains a barrier to well-being and long-term care despite effective antiretroviral therapy. We conducted a cross-sectional analysis using baseline data from a prospective real-world cohort of adults receiving routine HIV care in northern Portugal. Overall HIV stigma was the primary outcome, and associations with sociodemographic, clinical, laboratory, behavioral, and patient-reported variables were examined using univariable and multivariable linear regression. Among 467 participants, the median overall stigma score was 30 (Q1–Q3, 26–35), and disclosure concerns had the highest median subscale score. The multivariable model was statistically significant, F(7,429) = 10.254, p < 0.001, adjusted R² = 0.129. Higher overall stigma was independently associated with HIV-1 viral load ≥ 200 copies/mL (B = 4.489, 95% CI 0.660 to 8.318, t = 2.304, p = 0.022), anxiety symptoms (B = 0.318 per point, 95% CI 0.120 to 0.515, t = 3.166, p = 0.002), and depressive symptoms (B = 0.236 per point, 95% CI 0.031 to 0.441, t = 2.259, p = 0.024). A history of opportunistic infection was associated with lower stigma (B = -1.826, 95% CI -3.524 to -0.128, t = -2.114, p = 0.035). Higher quality-of-life scores were consistently associated with lower stigma (t values ranging from − 10.690 to -4.161, all p < 0.001). These findings support routine stigma-sensitive and psychologically informed HIV care to identify psychosocial needs and potentially improve well-being and treatment outcomes.


  • Open Access

    ANTIMICROBIAL OPTIMIZATION AFTER POSITIVE PNEUMOCOCCAL URINARY ANTIGEN TESTING IN HOSPITALIZED COMMUNITY-ACQUIRED PNEUMONIA: A RETROSPECTIVE COHORT STUDY

    by Maria Donga, Ana Gorgulho, Francisca Bartilotti, Dara Mbanze, Rita Menezes, Cristóvão Figueiredo, Joana Fragoso, Sofia Nunes, Daniel Coutinho, Gabriela Abreu, et al.

    Background: Pneumococcal urinary antigen testing (PUAT) rapidly supports pneumococcal etiology in community-acquired pneumonia (CAP), but its impact on antimicrobial optimization in routine care remains uncertain. Objectives: To evaluate antimicrobial spectrum narrowing after positive PUAT in hospitalized adults with CAP and to describe other antimicrobial optimization actions. Methods: We conducted a retrospective observational cohort study at a Portuguese tertiary hospital including adults hospitalized with CAP and positive PUAT between January 2020 and December 2024. The primary endpoint was antimicrobial spectrum narrowing. Absence or early discontinuation of atypical coverage and intravenous-to-oral switch were analyzed separately. Results: Among 332 episodes, antimicrobial spectrum narrowing occurred in 30 (9.0%), after a median of 3 days (Q1-Q3, 2-4). De-escalation to ampicillin or amoxicillin occurred in 7 episodes (2.1%). Narrowing was less frequent among patients initially treated with amoxicillin/clavulanate (10.0% vs 43.7%; p<0.001) and more frequent among those receiving broader-spectrum beta-lactams other than ceftriaxone or amoxicillin/clavulanate (20.0% vs 6.3%; p=0.007). Absence or early discontinuation of atypical coverage occurred in 158 episodes (47.6%) and intravenous-to-oral switch in 71 (21.4%). Narrowing and intravenous-to-oral switch were associated with shorter length of stay, but these associations were considered exploratory because of potential confounding by clinical stability. Conclusions: In hospitalized PUAT-positive CAP, antimicrobial spectrum narrowing was uncommon, whereas atypical coverage optimization was the most frequent prescribing change. Structured reassessment pathways may be needed to translate PUAT results into safe, microbiology-guided antimicrobial optimization.

  • Open Access

    HIV Infection in Portugal: Measuring the Time Between Linkage to Care and Antiretroviral Therapy Initiation

    by Ana Virgolino, Carolina Ferraz, Vanessa Nicolau, Rui Cortes, Aida Pereira, Fernando Maltez, João Paulo Caldas, João Lourinho, Maria Alves, Inês Caetano, et al.

    Background/Objectives: The timely initiation of antiretroviral therapy (ART) in persons living with HIV (PLWH) can improve clinical outcomes. However, ART commencement is often delayed. Portugal, despite having one of the highest new HIV diagnosis rates within the European Union, has limited available national-level data. Prior evidence from 2017 to 2018 suggests that the average time to ART initiation exceeds the recommendations for optimal patient benefits. This study aimed to determine the number of days from the first hospital appointment to the commencement of ART among newly diagnosed PLWH in Portugal between 2017 and 2022 at the national level and across different hospitals. It was hypothesized that newly diagnosed PLWH in Portugal experience a delay in ART initiation beyond the recommended timeframe. Methods: A retrospective analysis of records from Portuguese public tertiary care hospitals, which manage most HIV patients, was conducted. Descriptive statistics (measures of central tendency, dispersion, and frequency) were applied, along with association tests and a binary logistic regression model to examine factors influencing the timing of ART initiation. Results: A total of 2229 cases (out of 3434 received) from 19 hospitals were considered eligible. The median time interval between the first hospital appointment and ART initiation was 29.00 days, with a decreasing tendency between 2017 and 2022. Patients initiating therapy after 14 days had higher CD4 levels and lower viral loads compared to those starting within 14 days, with statistical significance. Conclusions: Continuous and regular monitoring of key indicators, such as the time to ART initiation, is pivotal for assessing the effectiveness of HIV treatment programs and pinpointing areas in need of improvement.